

MNKD Products & Pipeline

■ Cardiometabolic
 ■ Orphan Lung

| Product | Targeted Indications | Pre-IND | Phase 1 | Phase 2 | Phase 3 | Approval |
|--|--------------------------|-------------------------|---------|---------|---------|----------|
| Afrezza® (insulin human) Inhalation Powder | T1DM / T2DM (adults) | Marketed | | | | Marketed |
| | T1DM / T2DM (pediatrics) | PDUFA: Q2 2026 | | | | |
| V-Go® All-in-One Insulin Delivery Patch | T1DM / T2DM (adults) | Marketed | | | | Marketed |
| FUROSCIX® (furosemide injection) <small>(marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)</small> | Edema from CHF / CKD | Marketed | | | | Marketed |
| FUROSCIX ReadyFlow™ Autoinjector | Edema from CHF / CKD | PDUFA: Q3 2026 | | | | |
| Bumetanide DPI <small>(MNKD-701)</small> | Edema from CHF / CKD | Pre-Clinical | | | | |
| Tyvaso DPI® (treprostinil) Inhalation Powder <small>(marketed by United Therapeutics)</small> | PAH / PH-ILD | Marketed | | | | Marketed |
| Nintedanib DPI <small>(MNKD-201)</small> | IPF | Phase 2 (INFLO-2 study) | | | | |
| Partner Program with United Therapeutics (MNKD-1501) | UNDISCLOSED | STAGE UNDISCLOSED | | | | |